Canine cardiology, a strategic area of expertise for Ceva, has benefited from substantial R&D investment. This investment has allowed the Group to develop, for the very first time in veterinary medicine, a molecule that was previously restricted to use in human cardiology: spironolactone.
More recently, Ceva was the first company proposing a combination of two actives (spironolactone and benazepril) for improving dogs quality of life, survival time and treatment compliance.
End of 2013, Ceva reached a new step in its strategy of innovation in canine cardiology by acquiring the Sogeval company. With Sogeval joining the Ceva group, Ceva not only enlarged its product portfolio for canine Congestive Heart Failure (CHF) but also acquired new expertise in the development and the production of new drug formulations and innovative solutions for improving treatment compliance.
Cardiac dogs are more and more diagnosed every day, and represent up to 15% of the dog population. Pet parents are expecting vets to treat their dogs and prolong their life, but also maintain a good quality of life and control the clinical signs of cardiac disease. As in humans, congestive heart failure requires several molecules, complementary thanks to their mode of action on heart and blood vessels. Ceva offers a wide cardiology range to help vets in their practice. Some molecules are aimed to limit the harmful effects of vasoconstriction and heart remodeling. Some others act on kidneys to stimulate water excretion as a retention (e.g. pulmonary oedema in lungs) can be observed in symptomatic patients due to cardiac decompensation.
As an innovative company, Ceva is not only providing vets with drugs but also with tools and continuous education on digital platform with videos performed by the most well-known experts of the international community. A digital application was also developed to help owners in measuring the sleeping respiratory rate of their dog, parameter indicating if their dog is well-controlled or not with his treatment and if a visit to the vet is required.
With the first drug developed for cats on the market, Ceva is the first pharmaceutical company to offer the possibility to veterinarians to prescribe an effective, and safe medication for the treatment of hypertension in cats.
Hypertension is called the silent killer. It has been shown that 1 in 6 cats aged over 7 years suffers from this disease. Hypertension is harmful to the body. In cats, it can cause damage to key body organs, including the eyes, kidneys, heart and brain.
Early diagnosis is key to fighting hypertension. It is therefore recommended to measure blood pressure at least once a year in cats over 7 years of age and in cats suffering from kidney disease or thyroid disease. Measuring blood pressure in cats is quick and easy and should be part of the annual health check of mature to older cats.
Treating hypertension is essential as it will prevent or limit the damage to important organs such as the eye, the kidneys, the heart and the brain. For instance early treatment can prevent the cat from getting blind due to high blood pressure. It will also improve cat’s quality of life and allow them to live longer a healthier life.
To help raising awareness in both vets and cat owners, Ceva is leading actions such as the “Hypertension month”. Training programmes, videos and leaflet for cat owners, booklets and practical tools on hypertension have been developed to accompany vets in their daily practice.
The aim is to help remind veterinarians to check mature and senior cats for hypertension, and to encourage cat owners to have their cat’s blood pressure checked regularly. For the benefit of their cat’s health – and their own!
From one country to another, product lines are adapted to local demand and regulatory requirements. For further information, please take a look at the Ceva Santé Animale site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.